サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1007154

多形性膠芽腫治療の世界市場：業界動向、市場シェア・規模・成長率・機会および予測（2021年～2026年）

Glioblastoma Multiforme Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026
出版日: | 発行: IMARC Services Private Limited | ページ情報: 英文 | 納期: 2～3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=134.29円
多形性膠芽腫治療の世界市場：業界動向、市場シェア・規模・成長率・機会および予測（2021年～2026年）
出版日: 2021年05月20日
発行: IMARC Services Private Limited
ページ情報: 英文
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の多形性膠芽腫治療市場は、2015年から2020年にかけて力強い成長を示しました。グレードIV星状細胞腫とも呼ばれる多形性膠芽腫は、悪性グレードIVの脳腫瘍であり、脳細胞内に急速に広がり、近くの細胞にも感染する可能性があります。急速な細胞変性が特徴であるため、脳に大きな圧力がかかり、激しい頭痛や発作を引き起こします。病気の正確な原因はまだわかっていませんが、ターコット症候群などのまれな遺伝性疾患を含むいくつかの要因がその原因であると考えられています。これは脳腫瘍の最も致命的な形態の1つであり、本質的に治療抵抗性であり、患者の診断後の生存期間は非常に短いです。この病気の現在の治療方法には、外科的切除、化学療法、および放射線療法などが含あります。2021年から2026年の間に世界の多形性膠芽腫治療の市場規模は、約9％のCAGRで拡大すると予想されています。

腫瘍性疾患の有病率の増加と世界中の老齢人口の増加は、市場成長を推進する主要な要因の1つとなっています。さらに、神経膠腫幹細胞の抵抗性に対抗する先進治療の開発も、市場成長にプラスの影響を与えています。また、癌および関連疾患の分子バイオテクノロジーおよび遺伝子治療における研究開発（R＆D）活動の増加により、さまざまな生物学的製剤の開発が促進されています。これらの薬は、既存の治療法の副作用を軽減するのに役立ち、患者の間でより広く受け入れられるようになります。さらに、ヘルスケアインフラを改善するために一部の政府によって行われたイニシアチブは、さまざまな治療法の利用可能性に対する意識の高まりとともに、市場に前向きな見通しを生み出すことがさらに見込まれています。

当レポートは、世界の多形性膠芽腫市場について調査しており、業界動向、市場予測、薬の種類・投与経路・分子の種類・流通チャネル・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 序文

第2章 範囲と調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界の多形性膠芽腫治療市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 薬の種類別の市場セグメンテーション
  • 分子の種類別の市場セグメンテーション
  • 投与経路別の市場セグメンテーション
  • 流通チャネル別の市場セグメンテーション
  • 地域別の市場セグメンテーション

第6章 薬の種類別の市場セグメンテーション

  • テモゾロミド
  • ベバシズマブ
  • カルムスチン
  • 放射線増感剤
  • その他

第7章 投与経路別の市場セグメンテーション

  • 経口
  • 非経口

第8章 分子の種類別の市場セグメンテーション

  • 小分子
  • 生物製剤

第9章 流通チャネル別の市場セグメンテーション

  • 病院
  • 薬局
  • その他

第10章 地域別の市場セグメンテーション

  • 北米
  • 欧州
  • アジア太平洋地域
  • 中東・アフリカ
  • ラテンアメリカ

第11章 SWOT分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業 のプロファイル
    • Sun Pharmaceutical Industries
    • Celldex Therapeutics
    • Pfizer
    • F.Hoffmann La Roche
    • Bristol-Myers Squibb
    • Teva Pharmaceuticals
    • Exelixis
    • Angiochem
    • Arbor Pharmaceuticals
図表

List of Figures

  • Figure 1: Global: Glioblastoma Multiforme Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Glioblastoma Multiforme Treatment Market: Sales Value (in Billion US$), 2015 - 2020
  • Figure 3: Global: Glioblastoma Multiforme Treatment Market: Breakup by Drug Type (in %), 2020
  • Figure 4: Global: Glioblastoma Multiforme Treatment Market: Breakup by Route of Administration (in %), 2020
  • Figure 5: Global: Glioblastoma Multiforme Treatment Market: Breakup by Type of Molecule (in %), 2020
  • Figure 6: Global: Glioblastoma Multiforme Treatment Market: Breakup by Distribution Channel (in %), 2020
  • Figure 7: Global: Glioblastoma Multiforme Treatment Market: Breakup by Region (in %), 2020
  • Figure 8: Global: Glioblastoma Multiforme Treatment Market Forecast: Sales Value (in Billion US$), 2021-2026
  • Figure 9: Global: Glioblastoma Multiforme Treatment Industry: SWOT Analysis
  • Figure 10: Global: Glioblastoma Multiforme Treatment Industry: Value Chain Analysis
  • Figure 11: Global: Glioblastoma Multiforme Treatment Industry: Porter's Five Forces Analysis
  • Figure 12: Global: Glioblastoma Multiforme Treatment (Temozolomide) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 13: Global: Glioblastoma Multiforme Treatment (Temozolomide) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 14: Global: Glioblastoma Multiforme Treatment (Bevacizumab) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 15: Global: Glioblastoma Multiforme Treatment (Bevacizumab) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 16: Global: Glioblastoma Multiforme Treatment (Carmustine) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 17: Global: Glioblastoma Multiforme Treatment (Carmustine) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 18: Global: Glioblastoma Multiforme Treatment (Radiosensitizers) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 19: Global: Glioblastoma Multiforme Treatment (Radiosensitizers) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 20: Global: Glioblastoma Multiforme Treatment (Other Drug Types) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 21: Global: Glioblastoma Multiforme Treatment (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 22: Global: Glioblastoma Multiforme Treatment (Oral) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 23: Global: Glioblastoma Multiforme Treatment (Oral) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 24: Global: Glioblastoma Multiforme Treatment (Parenteral) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 25: Global: Glioblastoma Multiforme Treatment (Parenteral) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 26: Global: Glioblastoma Multiforme Treatment (Small Molecule) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 27: Global: Glioblastoma Multiforme Treatment (Small Molecule) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 28: Global: Glioblastoma Multiforme Treatment (Biologics) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 29: Global: Glioblastoma Multiforme Treatment (Biologics) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 30: Global: Glioblastoma Multiforme Treatment Market: Sales through Hospitals (in Million US$), 2015 & 2020
  • Figure 31: Global: Glioblastoma Multiforme Treatment Market Forecast: Sales through Hospitals (in Million US$), 2021-2026
  • Figure 32: Global: Glioblastoma Multiforme Treatment Market: Sales through Pharmacies (in Million US$), 2015 & 2020
  • Figure 33: Global: Glioblastoma Multiforme Treatment Market Forecast: Sales through Pharmacies (in Million US$), 2021-2026
  • Figure 34: Global: Glioblastoma Multiforme Treatment Market: Sales through Other Distribution Channels (in Million US$), 2015 & 2020
  • Figure 35: Global: Glioblastoma Multiforme Treatment Market Forecast: Sales through Other Distribution Channels (in Million US$), 2021-2026
  • Figure 36: North America: Glioblastoma Multiforme Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 37: North America: Glioblastoma Multiforme Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 38: Europe: Glioblastoma Multiforme Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 39: Europe: Glioblastoma Multiforme Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 40: Asia Pacific: Glioblastoma Multiforme Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 41: Asia Pacific: Glioblastoma Multiforme Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 42: Middle East and Africa: Glioblastoma Multiforme Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 43: Middle East and Africa: Glioblastoma Multiforme Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 44: Latin America: Glioblastoma Multiforme Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 45: Latin America: Glioblastoma Multiforme Treatment Market Forecast: Sales Value (in Million US$), 2021-2026

List of Tables

  • Table 1: Global: Glioblastoma Multiforme Treatment Market: Key Industry Highlights, 2020 and 2026
  • Table 2: Global: Glioblastoma Multiforme Treatment Market Forecast: Breakup by Drug Type (in Million US$), 2021-2026
  • Table 3: Global: Glioblastoma Multiforme Treatment Market Forecast: Breakup by Route of Administration (in Million US$), 2021-2026
  • Table 4: Global: Glioblastoma Multiforme Treatment Market Forecast: Breakup by Type of Molecule (in Million US$), 2021-2026
  • Table 5: Global: Glioblastoma Multiforme Treatment Market Forecast: Breakup by Distribution Channel (in Million US$), 2021-2026
  • Table 6: Global: Glioblastoma Multiforme Treatment Market Forecast: Breakup by Region (in Million US$), 2021-2026
  • Table 7: Global: Glioblastoma Multiforme Treatment Market: Competitive Structure
  • Table 8: Global: Glioblastoma Multiforme Treatment Market: Key Players
目次
Product Code: SR1020C240_Report

The global glioblastoma multiforme treatment market exhibited strong growth during 2015-2020. Glioblastoma multiforme, also known as grade IV astrocytoma, is a malignant grade IV brain tumor that rapidly spreads within the brain cells and can also infect the nearby cells. Since it is characterized by rapid cell degeneration, it creates immense pressure on the brain resulting in severe headaches and seizures. Although the exact cause of the diseases is still unknown, several factors including rare hereditary disorders such as Turcot syndrome are believed to be its cause. It is one of the most lethal forms of brain cancer and is treatment-resistant in nature, wherein the patient has an extremely short survival period post-diagnosis. The current treatment procedure of the disease includes surgical resection, chemotherapy and radiation. Looking forward, IMARC Group expects the global glioblastoma multiforme treatment market to grow at a CAGR of around 9% during 2021-2026.

Increasing prevalence of oncological diseases and a growing geriatric population across the globe are among the key factors driving the market growth. Furthermore, the development of advanced treatment methods that counter the resistive properties of glioma stem cells is also positively influencing the market growth. Additionally, increasing research and development (R&D) activities in molecular biotechnology and gene therapy for cancer and related diseases have facilitated the development of various biological drugs. These drugs assist in diminishing the side-effects of the existing treatment methods, thus creating broader acceptance amongst patients. Moreover, initiatives undertaken by several governments across the globe to improve healthcare infrastructure, along with the rising awareness of the availability of various therapies, are further expected to create a positive outlook for the market.

IMARC Group's latest report provides a deep insight into the global glioblastoma multiforme treatment market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the glioblastoma multiforme treatment market in any manner.

Report Coverage:

  • Historical, Current and Future Market Trends

Market Breakup by Drug Type:

  • Temozolomide
  • Bevacizumab
  • Carmustine
  • Radiosensitizers
  • Others

Market Breakup by Route of Administration:

  • Oral
  • Parenteral

Market Breakup by Type of Molecule:

  • Small Molecule
  • Biologics

Market Breakup by Distribution Channel:

  • Hospitals
  • Pharmacies
  • Others

Market Breakup by Region:

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America

Competitive Landscape:

  • The report has also analysed the competitive landscape of the market with some of the key players being Sun Pharmaceutical Industries, Celldex Therapeutics, Pfizer, F. Hoffmann La Roche, Bristol-Myers Squibb, Teva Pharmaceuticals, Exelixis, Angiochem, Arbor Pharmaceuticals, etc.

Key Questions Answered in This Report:

  • How has the global glioblastoma multiforme treatment market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global glioblastoma multiforme treatment industry?
  • What are the key regional markets in the global glioblastoma multiforme treatment industry?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the type of molecule?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the global glioblastoma multiforme treatment industry?
  • What are the key driving factors and challenges in the global glioblastoma multiforme treatment industry?
  • What is the structure of the global glioblastoma multiforme treatment industry and who are the key players?
  • What is the degree of competition in the global glioblastoma multiforme treatment industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Glioblastoma Multiforme Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Drug Type
  • 5.5 Market Breakup by Route of Administration
  • 5.6 Market Breakup by Type of Molecule
  • 5.7 Market Breakup by Distribution Channel
  • 5.8 Market Breakup by Region
  • 5.9 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Temozolomide
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Bevacizumab
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Carmustine
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Radiosensitizers
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Oral
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Parenteral
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Type of Molecule

  • 8.1 Small Molecule
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Biologics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Europe
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Asia Pacific
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Middle East and Africa
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast
  • 10.5 Latin America
    • 10.5.1 Market Trends
    • 10.5.2 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Sun Pharmaceutical Industries
    • 15.3.2 Celldex Therapeutics
    • 15.3.3 Pfizer
    • 15.3.4 F.Hoffmann La Roche
    • 15.3.5 Bristol-Myers Squibb
    • 15.3.6 Teva Pharmaceuticals
    • 15.3.7 Exelixis
    • 15.3.8 Angiochem
    • 15.3.9 Arbor Pharmaceuticals